| Product Unit Size | Cost | Quantity | Stock |
|---|
ARRY-162 is an orally bioavailable noncompetitive inhibitor of MEK1/2 and ERK that shows anticancer chemotherapeutic activity. Inhibition of MEK inhibits downstream signaling by IL-1, IL-6, and TNF. ARRY-162 inhibits proliferation in melanoma, non-small-cell lung cancer (NSCLC), head/neck cancer, and pancreatic cancer models.
| Cas No. | 606143-89-9 |
|---|---|
| Purity | ≥99% |
| Formula | C17H15BrF2N4O3 |
| Formula Wt. | 441.23 |
| IUPAC Name | 6-(4-bromo-2-fluoroanilino)-7-fluoro-N-(2-hydroxyethoxy)-3- methylbenzimidazole-5-carboxamide |
| Synonym | MEK162, Binimetinib |
| Solubility | DMSO 88 mg/mL warmed (199.44 mM) Water Insoluble Ethanol Insoluble |
| Appearance | White Crystal Powder |
| Store Temp | -20°C |
|---|---|
| Ship Temp | Ambient |
| MSDS | |
|---|---|
| Info Sheet | |
| Brochures |
www.clinicaltrials.gov/show/NCT00959127
